EBGLYSS DIN 02549131
Status: Marketed
Holder: ELI LILLY CANADA INC
Available to quote
Health Canada record
| Active ingredient(s) | LEBRIKIZUMAB 250 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | D11AH10 LEBRIKIZUMAB |
|---|
| Original market date | 26-Nov-2024 |
|---|
| Current status date | 26-Nov-2024 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Eli Lilly Canada Inc. — licence 100164, currently licensed, last inspection rating C (2026-03-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing LEBRIKIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02549123 | EBGLYSS | ELI LILLY CANADA INC | Solution | LEBRIKIZUMAB 250 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 33499 | 2024-06-24 | New Drug Submission (NDS) | |
Request a quote for EBGLYSS
How to read a Canadian DIN record